How to prepare an investigator brochure for an IND

What should an investigator brochure for an IND contain?

Where required under 312.55, the brochure brings together product and formulation information, pharmacology and toxicology, pharmacokinetics, prior human safety and effectiveness findings, and anticipated risks and precautions. Write from identified source versions and cutoffs. Connect the evidence to the actual study controls, distinguish observations from interpretation, and maintain a separate process for timely communication of important new safety information.

Before you begin

IND investigator-brochure preparation where required under 21 CFR 312.55. Sponsor-investigator and other contextual distinctions matter. This is not prescribing information and does not authorize clinical use.

What you will prepare: A versioned evidence synthesis for investigators, with transparent risks, uncertainties and links to the actual study controls.

Define the product, audience and evidence cutoff

Identify the investigational product and formulation, development program, intended investigators and cutoff. Section 312.23(a)(5) describes the brochure’s drug information, nonclinical and human findings, disposition, anticipated risks and precautions. Start from the actual reports and assessed safety information, not from a marketing slide deck. Establish applicability under 312.55 with the sponsor’s regulatory owner.

Explain the evidence without promoting the product

Organize the narrative around what investigators need to understand: product identity, pharmacology/toxicology, pharmacokinetics, available human experience and relevant risks or monitoring. Identify species, population, route, exposure and limitations when interpreting findings. Distinguish a related-drug concern from an observed event with this product. Trace practical precautions to the assessed evidence and appropriate protocol controls; the writer should not invent medical instructions.

Reconcile new evidence with existing study documents

Maintain a change summary and a source map so the sponsor can assess consequences for protocols, consent information and investigator communication. Do not defer time-sensitive safety assessment simply because the next brochure revision is scheduled later. Confirm the actual sponsor review and distribution process. A revised brochure in an annual submission is not by itself proof that every investigator received the update.

Fictional example: an unresolved exposure comparison

A draft calls an animal exposure margin reassuring, but the human exposure estimate comes from a different formulation. Flag the comparison, identify both sources and obtain the scientific owner’s assessment. Preserve the uncertainty until the comparison is justified. If the human cutoff changes, reconcile the safety population and study inventory before updating totals; do not change only the headline number.

Build an evidence-to-precaution record before writing the synthesis

The brochure needs to help an investigator understand what is known, what remains uncertain and how the assessed findings affect investigational use. A sequence of study abstracts can leave those connections unexplained. Use a working record to make each important interpretation reviewable.

Reconcile the study inventory before updating aggregate totals. A participant counted in an original study and an extension may not represent two distinct exposed people. Define the counting method, distinguish participants from exposure periods, and reconcile the data cutoff across safety, pharmacokinetics and the narrative. Where sources use different cutoffs, identify them rather than presenting a falsely uniform dataset.

Fictional synthesis exercise: a table records eight adverse events in five participants, while the draft says eight participants experienced the event. Correct the counting unit against the source, then inspect the nearby percentage and denominator. A related-drug report raises the same concern but does not establish causality for the investigational product. Keep that evidence separately attributed and obtain the medical assessment of its relevance. The correction should propagate to the summary and risk discussion, not just the table caption.

Section 312.55(a) requires a sponsor other than a sponsor-investigator to provide the brochure to each participating investigator before the investigation begins. Record the applicability decision and distribution evidence. The sponsor-investigator distinction in that paragraph should not become a blanket conclusion that no evidence synthesis, safety information or other IND responsibilities apply.

Under 312.55(b), investigators must be kept informed as the investigation proceeds. Revised brochures are one communication method; reports, letters and other appropriate means are also contemplated. Important safety information follows 312.32. Section 312.33(d) addresses the revised brochure in the annual report if it has been revised; it does not make the next annual report a safe waiting point for urgent information.

At release, reconcile the general investigational plan, affected protocols and the communication record. Use the IND annual-report guide for that separate submission task. A clean brochure PDF and a filed copy do not, by themselves, prove that the relevant investigators received an important update.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides